Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease - PubMed (original) (raw)
Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease
Li Wei et al. Ann Intern Med. 2004.
Abstract
Background: Glucocorticoids have adverse systemic effects, including obesity, hypertension, and hyperglycemia, that may predispose to cardiovascular disease. The effect of glucocorticoid use on cardiovascular disease has not been quantified.
Objective: To test the hypothesis that users of exogenous glucocorticoids have an increased risk for cardiovascular disease.
Design: A cohort study using a record linkage database.
Setting: Tayside, Scotland, United Kingdom.
Patients: 68,781 glucocorticoid users and 82,202 nonusers without previous hospitalization for cardiovascular disease who were studied between 1993 and 1996.
Measurements: The average daily dose of glucocorticoid exposure during follow-up was categorized as low (inhaled, nasal, and topical only), medium (oral, rectal, or parenteral <7.5 mg of prednisolone equivalent), or high (> or =7.5 mg of prednisolone equivalent). Poisson regression model, sensitivity analysis, and propensity score methods were used to investigate the association between glucocorticoid exposure and cardiovascular outcome.
Results: 4383 cardiovascular events occurred in 257,487 person-years of follow-up for a rate of 17.0 (95% CI, 16.5 to 17.5) per 1000 person-years in the comparator group, and 5068 events occurred in 212,287 person-years for a rate of 23.9 (CI, 23.2 to 24.5) per 1000 person-years in the group exposed to glucocorticoids (22.1, 27.2, and 76.5 in low, medium, and high groups, respectively). The absolute risk difference was 6.9 (CI, 6.0 to 7.7) per 1000 person-years (5.1, 10.1, and 59.4, respectively). After adjustment for known covariates, the relative risk for a cardiovascular event in patients receiving high-dose glucocorticoids was 2.56 (CI, 2.18 to 2.99).
Limitations: Because the data were observational, residual confounding cannot be excluded.
Conclusion: Treatment with high-dose glucocorticoids seemed to be associated with increased risk for cardiovascular disease.
Summary for patients in
- Summaries for patients. Glucocorticoid medications and the risk for cardiovascular disease.
[No authors listed] [No authors listed] Ann Intern Med. 2004 Nov 16;141(10):I58. doi: 10.7326/0003-4819-141-10-200411160-00003. Ann Intern Med. 2004. PMID: 15545672 No abstract available.
Similar articles
- Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: A population-based cohort study.
Pujades-Rodriguez M, Morgan AW, Cubbon RM, Wu J. Pujades-Rodriguez M, et al. PLoS Med. 2020 Dec 3;17(12):e1003432. doi: 10.1371/journal.pmed.1003432. eCollection 2020 Dec. PLoS Med. 2020. PMID: 33270649 Free PMC article. - Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study.
Souverein PC, Berard A, Van Staa TP, Cooper C, Egberts AC, Leufkens HG, Walker BR. Souverein PC, et al. Heart. 2004 Aug;90(8):859-65. doi: 10.1136/hrt.2003.020180. Heart. 2004. PMID: 15253953 Free PMC article. - Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study.
Johannesdottir SA, Horváth-Puhó E, Dekkers OM, Cannegieter SC, Jørgensen JO, Ehrenstein V, Vandenbroucke JP, Pedersen L, Sørensen HT. Johannesdottir SA, et al. JAMA Intern Med. 2013 May 13;173(9):743-52. doi: 10.1001/jamainternmed.2013.122. JAMA Intern Med. 2013. PMID: 23546607 - Aspirin Use in Adults: Cancer, All-Cause Mortality, and Harms: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet].
Whitlock EP, Williams SB, Burda BU, Feightner A, Beil T. Whitlock EP, et al. Rockville (MD): Agency for Healthcare Research and Quality (US); 2015 Sep. Report No.: 13-05193-EF-1. Rockville (MD): Agency for Healthcare Research and Quality (US); 2015 Sep. Report No.: 13-05193-EF-1. PMID: 26491756 Free Books & Documents. Review. - Adverse events of glucocorticoids during treatment of rheumatoid arthritis: lessons from cohort and registry studies.
W J Bijlsma J, Buttgereit F. W J Bijlsma J, et al. Rheumatology (Oxford). 2016 Dec;55(suppl 2):ii3-ii5. doi: 10.1093/rheumatology/kew344. Rheumatology (Oxford). 2016. PMID: 27856654 Review.
Cited by
- Assessment of cardiovascular risk in patients with ANCA-associated vasculitis: A systematic review and meta-analysis.
Goyal A, Abbasi HQ, Mashkoor Y, Khan AM, Sulaiman SA, Daoud M, Bansal K. Goyal A, et al. Int J Cardiol Cardiovasc Risk Prev. 2024 Sep 25;23:200334. doi: 10.1016/j.ijcrp.2024.200334. eCollection 2024 Dec. Int J Cardiol Cardiovasc Risk Prev. 2024. PMID: 39417001 Free PMC article. Review. - Prenatal glucocorticoids exposure and adverse cardiovascular effects in offspring.
Zhao C, He L, Li L, Deng F, Zhang M, Wang C, Qiu J, Gao Q. Zhao C, et al. Front Endocrinol (Lausanne). 2024 Sep 16;15:1430334. doi: 10.3389/fendo.2024.1430334. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39351527 Free PMC article. Review. - Managing Cardiovascular Risk in Patients with Autoimmune Diseases: Insights from a Nutritional Perspective.
Chen H, Liu L, Wang Y, Hong L, Pan J, Yu X, Dai H. Chen H, et al. Curr Nutr Rep. 2024 Dec;13(4):718-728. doi: 10.1007/s13668-024-00563-7. Epub 2024 Jul 30. Curr Nutr Rep. 2024. PMID: 39078574 Review. - Clinical courses and predictors of left ventricular systolic dysfunction in systemic sclerosis: A cohort study.
Werakiat J, Pussadhamma B, Mahakkanukrauh A, Suwannaroj S, Foocharoen C. Werakiat J, et al. Rheumatol Immunol Res. 2024 Jul 15;5(2):107-116. doi: 10.1515/rir-2024-0014. eCollection 2024 Jun. Rheumatol Immunol Res. 2024. PMID: 39015847 Free PMC article. - Association of Cardiovascular Outcomes With Low-Dose Glucocorticoid Prescription in Patients With Rheumatoid Arthritis.
Coburn BW, Baker JF, Hsu JY, Wu Q, Xie F, Curtis JR, George MD. Coburn BW, et al. Arthritis Rheumatol. 2024 Nov;76(11):1585-1593. doi: 10.1002/art.42928. Epub 2024 Jul 23. Arthritis Rheumatol. 2024. PMID: 38923870
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical